Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- (-) Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 116 Results
NPC Releases Updated Guiding Practices to Improve Patient-Centricity in Value Assessments
The Guiding Practices include 33 specific recommendations to ensure value assessments account for the full value pharmaceuticals provide to patients and society
Guiding Practices for Patient-Centered Value Assessment (2024)
NPC has updated its Guiding Practices for Patient-Centered Value Assessment. This update of NPC's guiding practices for US value assessment will help inform the growing importance of this tool to…
NPC Comments on Proposed Changes for ICER Value Assessment Framework
NPC's comments highlight key concerns related to proposed changes to ICER's 2023 Value Assessment Framework.
NPC Shares Input on CMS’ Data Collection Requirements
NPC comments offer input on CMS' approach to data collection that would inform the agency's implementation of provisions within the Inflation Reduction Act that enable government price-setting for…
Medicaid Best Price Reforms Can Encourage Innovative Payment Arrangements for Chronic Therapies
This NPC study extends previous work analyzing reforms to CMS’ Medicaid Best Price reporting rules to encourage the uptake of value-based purchasing agreements for chronic disease treatments.
The President’s victory lap on the success of price controls is premature
In a commentary published in the Sarasota Herald-Tribune, NPC's John M. O’Brien discusses the potential effects of new price controls and what the future holds for Medicare.
ICER Misses…Again
The latest Unsupported Price Increase Report from ICER lacks balance, uses flawed methods and may harm patients.
After 30 years of 340B, it's time for data and an honest conversation
In a commentary published in STAT, NPC's John M. O’Brien outlines why transparency is essential to assessing the true impact of 340B.
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
Study shows the impact of a more holistic approach to assessing value and how it can help address gaps within conventional value assessment.
Characterizing Health Plan Evidence Review Practices
The study finds that some plans updated the evidence in their coverage policies for specialty medicines more often than others, and the type of evidence plans cited in their coverage policies…
Health Care Spending Effectiveness: Estimates Suggest that Spending Improved U.S. Health from 1996 to 2016
This research assessed the effectiveness of U.S. health care spending by comparing changes in health outcomes and found that, overall, innovations in health care are creating more cost-effective care…
Health Care Spending Guiding Principles
NPC established a set of principles to assess health care spending estimates and policies to ensure alignment with the goals of patient-centered care.
How Reforms Can Enable Payment Innovation That Drives Value
This NPC study models the effects of recent and proposed payment reforms related to CMS' best price reporting rules and sheds light on which approaches may encourage the adoption of value-based…
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and…
Making Our Health Care System More Supportive and Inclusive for Caregivers
NPC President and CEO John M. O'Brien writes about how we can better incorporate the needs of caregivers into our health care system and provide them the support they…
Creating a Dialogue or Just Playing for Headlines? Third Time Isn’t the Charm for ICER’s Pricing Report
Selectively picking the data to arrive at a convenient narrative — like the Institute for Clinical and Economic Review does in its third drug pricing report — should not be mistaken for good…